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How to… Diagnose and Manage Proteinuria in Chronic 
Kidney Disease in Practice 
Introduction 
Chronic kidney disease (CKD) is one of the most commonly diagnosed diseases in cats and 
prevalence increases with advancing age, ranging from 31% to 81% in geriatric populations. 
Diagnostic work-up generally includes blood and urine testing, blood pressure measurement as 
well as imaging and should be performed in the presence of historical and clinical findings 
suggestive of CKD, such as lethargy, inappetence, weight loss, dehydration, polyuria/polydipsia, 
altered kidney size, systemic hypertension and urine specific gravity (USG) < 1.035. CKD 
management consists of diet modification, treatment of systemic hypertension and treatment of 
proteinuria as well as supportive and symptomatic treatments on a case by case basis. Although 
there is no treatment for CKD, early diagnosis and disease management in conjunction with home 
monitoring result in delay of disease progression and, ultimately, improved prognosis and quality 
of life. 
Diagnosis and Staging of CKD 
Following diagnosis, staging is performed according to the International Renal Interest Society 
(IRIS) guidelines. It is important to note that staging can only be undertaken in patients with 
normal hydration status and stable renal function by measuring fasting serum/plasma creatinine 
concentration (Table 1). Substaging is performed for urine protein creatinine ratio (UPC; Table 2) 
and systolic blood pressure (SBP; Table 3). 
Table 1: IRIS Staging based on fasting blood creatinine concentration (μmol/l) 
Stage Creatinine Clinical Comments 
At risk < 140 At risk of developing CKD based on history (age, breed, drugs) 
Stage 1 < 140 Nonazotaemic. Other renal abnormalities, such as low USG, renal 
proteinuria etc present. 
Stage 2 140 – 250  Mild renal azotaemia. Mild clinical signs (PU/PD) or absent. 
Stage 3 251 – 440  Moderate renal azotaemia. Many renal and extra-renal signs. 
Stage 4 > 440 Severe renal azotaemia. ↑risk of systemic signs and uraemic crisis. 
 
Table 2: IRIS Substaging by Proteinuria (UPC) 
Substage Catsa 
Non proteinuric <0.2 
Borderline proteinuric 0.2-0.4 
Proteinuric >0.4 
aNormal intact male cats can have a UPC ≤ 0.6. 
Table 3: IRIS Substaging by Systolic Blood Pressure (mmHg) 
Substage Systolic Blood 
Pressure 
Risk of Future Target Organ Damage 
Normotensive < 150 Minimal 
Borderline 
Hypertensive 
150 – 159  Low 
Hypertensive 160 – 179  Moderate 
Severely 
Hypertensive 
≥ 180 High 
Assessment of Proteinuria 
It is estimated that 50-60% of cats with CKD are non-proteinuric, whilst overt proteinuria (UPC 
>0.4) is seen in approximately 20% of cats with CKD. Recognition and management of proteinuria 
is of paramount importance, as proteinuria has been strongly associated with CKD progression 
and survival. Assessment of proteinuria includes identification of its localisation, persistence and 
magnitude.  
Localisation 
The origin of proteinuria can be pre-renal, renal or post-renal. 
• Pre-renal proteinuria results from the inability of the glomerulus, the filtration unit of the 
kidney, to absorb high quantities of specific proteins in disease processes such as multiple 
myeloma or intravascular haemolysis. Specific diagnostics such as serum protein 
electrophoresis need to be undertaken in addition to routine blood work to diagnose pre-
renal proteinuria. 
 
• Renal proteinuria can be functional or pathological. Functional renal proteinuria can be 
seen as a result of fever, seizures or strenuous exercise, although this is rarely recognised 
in cats. Pathological renal proteinuria can be the result of damage in the glomerulus 
(glomerular proteinuria) or in the renal tubules and interstitium (tubulointerstitial proteinuria). 
Primary glomerular proteinuria is rarely seen in cats with CKD as they mostly exhibit 
tubulointerstitial proteinuria. Secondary glomerular proteinuria, on the other hand, is more 
common and occurs due to systemic hypertension. In these cases, management of 
hypertension will usually resolve the proteinuria. 
 
• Post-renal proteinuria occurs as a result of exudative or haemorrhagic processes affecting 
the lower urinary or genital tract e.g. urinary tract infection. This can be excluded by 
performing urine sediment examination. 
Persistence  
Proteinuria is considered persistent if confirmed at least three times, two or more weeks apart.  
Magnitude 
Different methods can be used to assess the magnitude of proteinuria. These are either semi-
quantitative, such as the “dipstick” or the Sulfosalicylic acid turbidimetric method (SSA) or 
quantitative, such as UPC and urine albumin. 
The reagent pad colorimetric method, also known as “dipstick”, primarily detects albumin in the 
urine. Although it is widely available and easy to use, false positive and false negative readings 
can occur with highly concentrated urine, very acidic or alkaline urine or pigmented urine. 
Particularly in the cat, sensitivity is 90% and specificity is only 11% (Lyon et al., 2010). 
The Sulfosalicylic acid turbidimetric method (SSA) performs better than the dipstick; however it 
cannot be run in-house and false positives or negatives can still occur. 
Moreover, both dipstick and SSA results need to be interpreted in conjunction with the USG and 
sediment examination. 
UPC should be performed in any cat with a positive dipstick reading either in-house or at a 
reference laboratory as it is considered the gold standard method of confirming and quantifying 
proteinuria. More specifically in cats, a single measurement in a free catch or cystocentesis 
sample correlates with 24-hour quantification (Adams et al., 1992), whilst there is excellent 
correlation between free catch and samples obtained via cystocentesis (Vilhena et al, 2015). As 
shown on Table 2, neutered cats are expected to have a UPC <0.2, however normal intact male 
cats can have <0.6, most likely due to the presence of urinary cauxin. 
Urine albumin can be measured in a reference laboratory only, however the clinical benefit of 
measuring urine albumin: creatinine ratio (UAC) over UPC hasn’t been demonstrated in cats 
(Jepson et al, 2009). 
Management of Proteinuria 
Based on current IRIS guidelines (Table 2), medical intervention for the management of 
proteinuria is needed in cats with a UPC >0.4. Nevertheless, some clinicians will advocate 
treatment of cats with borderline proteinuria, as non-proteinuric cats have been shown to have a 
better prognosis compared to cats with even borderline proteinuria. 
Inhibition of the renin-angiotensin-aldosterone-system (RAAS) which is activated in CKD has been 
the main therapeutic target in the approach to reduce proteinuria. RAAS activation (Figure 1) 
promotes proteinuria and, in the long term, results in progressive renal injury. Agents targeting 
RAAS (Table 4) licensed for the management of proteinuria in cats with CKD are the angiotensin-
converting enzyme inhibitor (ACEi) benazepril and angiotensin-receptor blocker (ARB) telmisartan. 
The aldosterone-receptor antagonist spironolactone can be used in dogs, whilst renin inhibitors 
are used in humans, but not dogs or cats. 
Table 4: RAAS inhibitors licensed for the management of proteinuria in cats with CKD in 
UK 
Class Drug Formulation Initial dose 
Angiotensin-converting enzyme 
inhibitors 
Benazepril Tablet 0.5-1.0 mg/kg PO q24hrs 
Angiotensin receptor blockers Telmisartan Oral solution 1 mg/kg PO q24hrs 
ACEi 
The use of ACEi has been shown to significantly reduce proteinuria in cats. However, no survival 
benefit has yet been shown, although studies to date have had a small sample size.  
Benazepril undergoes both renal and hepatic elimination which would be beneficial compared to 
enalapril with regards to safety when administered in cats with IRIS CKD Stage 3 or 4. However, 
there is no current evidence to suggest that one ACEi is superior to another and benazepril is the 
only ACEi licensed in the UK for the management of proteinuria in cats with CKD. 
ACEi should only be administered in stable, euhydrated and normotensive cats and greater care 
should be taken in cats with IRIS stage IV CKD since their administration can result in 
hypotension, worsening of pre-existing azotaemia and, rarely, hyperkalaemia. 
ARB 
The AT-II type-2 receptor (AT2) is considered to have renoprotective actions and angiotensin 
receptor blockers selectively inhibit AT1, preventing 
Losartan wasn't shown to be effective in reducing proteinuria in cats, however the study wasn't 
performed in patients with naturally occurring disease (Jenkins et al, 2015). Telmisartan is the only 
ARB licensed in the UK for the management of proteinuria in cats with CKD. In a study comparing 
benazepril and telmisartan, a greater decrease in UPC was observed over time in cats receiving 
telmisartan (Sent et al, 2015). 
Combination Therapy 
Combination therapy with an ACEi and an ARB may be indicated if either is not effective in 
reducing proteinuria. As there are no studies evaluating the safety of combination therapy in cats 
and care should be exercised as combination therapy increased risk of kidney failure and mortality 
in a subset of human patients. 
Aldosterone Breakthrough 
Aldosterone breakthrough refers to a phenomenon where serum aldosterone concentration 
increases over time even if maximal doses of RAAS inhibitors are received. In ACE-escape, on 
the other hand, there is ongoing AT-II production due to incomplete inhibition of conversion of AT-I 
to AT-II in patients administered ACEi. Both phenomena occur over time in a subset of human 
patients, but the mechanisms and incidence are unclear in cats. Consequently, as there are no 
published studies exploring the use of aldosterone receptor antagonists such as spironolactone in 
cats with proteinuric CKD, its use would be off licence and may be considered in a cat with high 
serum aldosterone concentration and persistent proteinuria despite treatment with ACEi and/or 
ARB. 
Renal Biopsy & Immunisuppressive Therapy 
Renal biopsy can provide information about the severity of underlying renal injury, but also 
potentially offer a definitive diagnosis. Contraindications to performing a renal biopsy include 
moderate or marked azotaemia, renal cystic disease, hydronephrosis, pyelonephritis, uncontrolled 
hypertension, severe anaemia or coagulopathy. 
Renal biopsy is indicated in cats with proteinuria of high, glomerular-level magnitude that haven't 
responded to RAAS inhibition, however results of a renal biopsy are unlikely to alter long-term 
management in cats with CKD as it has been shown that over 50% have tubulointerstitial nephritis 
(Chakrabarti et al, 2012; DiBartola et al, 1987). Consequently, immune-mediated 
glomerulonephritis is considered rare in cats and immunossuppressive treatment should be 
considered only if this has been confirmed by performing a renal biopsy. It should be noted that no 
Renal Standardization Projects have been undertaken in cats to date and no consensus 
guidelines have been produced. 
Adjunctive therapies 
Dietary therapy: Feeding of renal diets is considered to decrease proteinuria, however they are 
rarely useful as a monotherapy. 
Omega 3 (n3) and Omega 6 (n6) Polyunsaturated fatty acids (PUFA): In study evaluating the 
feeding of various renal diets to cats with CKD, all studied diets improved survival. Although the 
diet with the highest eicosapentaenoic acid (n3) content was associated with the longest survival, 
a causal relationship wasn't proven and therefore there are no specific dietary supplementations 
recommended like in dogs. 
Antithrombotic therapy: Thromboembolism is often recognised in dogs but rarely in cats and, to 
the author's knowledge, there are no published studies in this species. 
Treatment monitoring 
A decreased UPC <0.4 is the optimal therapeutic target for proteinuric CKD in cats, although this 
is not achieved in many patients. Following initiation or a change in dose of RAAS blockade 
therapy, clinical signs, creatinine, urea and SBP should be measured after 5-7 days. Treatment 
modification consisting of ACEi or ARB dose reduction or cessation is indicated if there is an 
increase in serum creatinine of >15-20% suggesting worsening renal function. 
Prognosis of Cats with Proteinuric CKD 
Proteinuria is a negative prognostic indicator in cats with CKD and multiple studies have 
demonstrated that the magnitude of proteinuria is inversely proportional to survival. Although in 
humans and dogs the reduction of proteinuria has been shown to improve survival and delay 
disease progression, the same has yet to be demonstrated in cats receiving anti-proteinuric 
treatment. 
Conclusion 
Management of proteinuria in cats with CKD is achieved by administering drugs that inhibit the 
RAAS system. Regular assessment of clinical and laboratory parameters is indicated and 
treatment tailored accordingly and to the individual cat. Adjunctive treatments might also be helpful 
in the management of proteinuria, however more studies are needed to prove their benefit. Most 
cats with CKD have tubulointerstitial nephritis rather than glomerular disease and, therefore, a 
renal biopsy is rarely indicated. Although a survival benefit has not yet been demonstrated, RAAS 
inhibition is recommended in cats with overt proteinuria. 
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Figure 1. The renin-angiotensin-aldosterone-system and its inhibitors. ACE, angiotensin-
converting enzyme, AT1; angiotensin II type-1 receptor, AT2, angiotensin II type-2 receptor.  
*Aldosterone receptor antagonists and renin inhibitors are not currently used in cats. 
